

Managing common infections NICE guideline Clostridium difficile infection: antimicrobial prescribing (Meeting 2) Minutes

Date: 12/11/19

Location: NICE Office, Manchester

Committee members present:

Tessa Lewis – Chair (TL)

Yarni Finney (YF)

Alastair Hay (AH)

Ian Hill-Smith (IH)

Susan Hopkins (SH)

Present for items 1 - 5

Amelia Joseph (AJ) Present for items part of 4 - 5

Marisa Lanzman (ML)
Paddy McMaster (PM)
Present for items 1 - 5

Expert witness:

Mark Wilcox Present for items 1 - 5

In attendance (NICE):

Alex Curwen (AC)

Rupert Franklin (RF)

Ruth Garnett (RG)

Johanna Hulme (JH)

James Jagroo (JJ)

Present for items 1 - 5

Greg Moran (GM) Present for items 1 - part of 4

Louise Picton (LP) Present for items 1 - 5
Ian Pye (IP) Present for items 1 - 5
Jonathan Underhill (JU) Present for items 1 - 5

Apologies:

Stephanie Dancer, Philip Howard

1. Welcome, introductions and apologies

The chair welcomed the committee members and attendees to Clostridium difficile infection (CDI) meeting 2 of the public health advisory committee D (managing common infections committee). The committee members and attendees introduced themselves.

The chair informed the committee that apologies had been received as noted above.

The chair outlined the objectives of the meeting, which included:

Discussion of evidence, draft recommendations for guidance on the treatment of Clostridium difficile infection: antimicrobial prescribing

2. Declaration of interests

The chair asked the committee to declare any new or relevant interests.

Name	Job title, organisation	Declarations of Interest
Susan Hopkins	Healthcare- Associated Infection & Antimicrobial Resistance	In charge of C.diff outputs for NHSE
	Deputy Director, National Infection Service, Public Health England	

The chair and a senior member of the NICE Development team (NDT) noted that the interests declared did not prevent the attendees from participating in the meeting at the chair's discretion.

3. Network meta-analysis training

SB gave a short training presentation on network meta-analysis.

4. Discussion of evidence, draft recommendations for guidance on the treatment of Clostridium difficile infection: antimicrobial prescribing

IP explained the role MW will have in the meeting and how the committee can ask the expert witness questions. The development team will be taking detailed notes on his responses to questions, which will then be sent to MW for ratification ahead of publication as expert witness testimony. This will form part of the evidence for the guideline.

RG gave a short background presentation outlining the topic and current published guidance.

JJ gave a presentation summarising the evidence for treating CDI. The committee discussed the evidence presented on antibiotics.

11:20 MW left the meeting.

11:20 GM left the meeting.

SB gave a presentation on antibiotic interventions for recurrent CDI.

The committee discussed the evidence presented.

12:10 AJ joined the meeting.

12:15 MW re-joined the meeting.

13:30 RF left the meeting.

JJ presented the evidence for CDI treatment in children. The committee discussed the evidence presented.

SB presented the evidence for faecal microbiota transplant (FMT). The committee discussed the evidence presented.

14:15 RF re-joined the meeting.

JJ presented evidence on prebiotics. The committee discussed the evidence presented.

JJ presented the evidence for probiotics in children. The committee discussed the evidence presented.

5. Any other business

No additional items were raised. The meeting closed at 16:00.